Does Rallies show Form 4 insider transactions for DNLI?

Yes. Rallies tracks DNLI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is DNLI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DNLI. It does not provide personalized investment advice.

DNLI (Denali Therapeutics Inc. Common Stock) Stock Analysis - Insider Trades

Denali Therapeutics Inc. Common Stock (DNLI) is a publicly traded Healthcare sector company. As of May 21, 2026, DNLI trades at $18.52 with a market cap of $2.92B and a P/E ratio of -6.34. DNLI moved +3.92% today. Year to date, DNLI is +17.54%; over the trailing twelve months it is +31.77%. Its 52-week range spans $10.57 to $33.33. Analyst consensus is strong buy with an average price target of $35.91. Rallies surfaces DNLI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading DNLI stock inside the company?

Recent DNLI insider activity includes Watts Ryan J. sold 35.20K, Schuth Alexander O. sold 17.22K, Ho Carole sold 806, Schuth Alexander O. sold 2.94K, and Ho Carole sold 2.94K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

DNLI Key Metrics

Key financial metrics for DNLI
Metric	Value
Price	$18.52
Market Cap	$2.92B
P/E Ratio	-6.34
EPS	$-2.97
Dividend Yield	0.00%
52-Week High	$33.33
52-Week Low	$10.57
Volume	1
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-512.54M
Gross Margin	0.00%

Recent DNLI Insider Trades

Watts Ryan J. sold 35.20K (~$580.77K) on Jan 6, 2026.
Schuth Alexander O. sold 17.22K (~$284.10K) on Jan 6, 2026.
Ho Carole sold 806 (~$11.80K) on Aug 13, 2025.
Schuth Alexander O. sold 2.94K (~$39.88K) on Aug 12, 2025.
Ho Carole sold 2.94K (~$39.88K) on Aug 12, 2025.

Latest DNLI News

Denali Therapeutics Secures Fast Track for Hunter Syndrome Drug with PDUFA April 2026 — Apr 1, 2026
FDA Extends Review Timeline for Denali's Tividenofusp Alfa MPS II Therapy Filing — Feb 10, 2026
Denali Therapeutics’ Brain-Penetrant ERT Cuts CSF Heparan Sulfate 91%, Eyes April 2026 PDUFA — Dec 30, 2025

DNLI Analyst Consensus

14 analysts cover DNLI: 0 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.91.

Common questions about DNLI

Who is trading DNLI stock inside the company?: Recent DNLI insider activity includes Watts Ryan J. sold 35.20K, Schuth Alexander O. sold 17.22K, Ho Carole sold 806, Schuth Alexander O. sold 2.94K, and Ho Carole sold 2.94K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for DNLI?: Yes. Rallies tracks DNLI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is DNLI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DNLI. It does not provide personalized investment advice.